(JNJ) Johnson & Johnson - Ratings and Ratios

Johnson & Johnson is a global healthcare conglomerate that develops, manufactures, and markets a diverse range of medical products and pharmaceuticals. The companys Innovative Medicine segment is a leader in various therapeutic areas, including immunology, oncology, and cardiovascular diseases, with a robust pipeline of innovative treatments. Meanwhile, the MedTech segment provides a broad portfolio of medical devices, including electrophysiology products, orthopaedic solutions, and surgical technologies, which are used to treat a range of medical conditions, from heart rhythm disorders to cataracts.

The companys diverse product portfolio is distributed through various channels, including wholesalers, hospitals, retailers, and healthcare professionals, allowing it to reach a wide customer base. With a history dating back to 1886, Johnson & Johnson has established itself as a trusted brand in the healthcare industry, with a strong presence in the global market. The companys commitment to innovation and quality has enabled it to maintain a competitive edge, with a range of products that address significant unmet medical needs.

Analyzing the and , we can observe that Johnson & Johnsons stock has been trading near its 52-week high, with a current price of 155.21. The stocks SMA20, SMA50, and SMA200 are all trending upwards, indicating a positive short-term and long-term outlook. Additionally, the companys P/E ratio of 17.10 and P/E Forward of 14.51 suggest that the stock is reasonably valued. With a Market Cap of 369524.24M USD and a RoE of 29.95, Johnson & Johnson demonstrates a strong financial position and ability to generate returns for shareholders.

Based on the and , our forecast suggests that Johnson & Johnsons stock is likely to continue its upward trend, with potential resistance at 163.5 and support at 153.0. The companys strong financials, diverse product portfolio, and commitment to innovation position it for long-term growth. As the stock approaches the resistance level of 163.5, investors may want to consider taking a buy position, with a stop-loss at 147.7, to capitalize on the potential upside.